nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—STK11—uterine cancer	0.288	0.625	CbGaD
Sunitinib—FGFR2—uterine cancer	0.173	0.375	CbGaD
Sunitinib—ABCG2—Dactinomycin—uterine cancer	0.0154	0.107	CbGbCtD
Sunitinib—CYP3A7—Progesterone—uterine cancer	0.0144	0.0998	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.0144	0.0998	CbGbCtD
Sunitinib—ABCC2—Carboplatin—uterine cancer	0.0115	0.0796	CbGbCtD
Sunitinib—CYP3A5—Progesterone—uterine cancer	0.0108	0.0749	CbGbCtD
Sunitinib—ABCG2—Carboplatin—uterine cancer	0.0104	0.072	CbGbCtD
Sunitinib—ABCC2—Etoposide—uterine cancer	0.00963	0.0669	CbGbCtD
Sunitinib—ABCG2—Etoposide—uterine cancer	0.00871	0.0605	CbGbCtD
Sunitinib—ABCB1—Progesterone—uterine cancer	0.00701	0.0487	CbGbCtD
Sunitinib—ABCC2—Doxorubicin—uterine cancer	0.00657	0.0456	CbGbCtD
Sunitinib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.00634	0.0441	CbGbCtD
Sunitinib—ABCG2—Doxorubicin—uterine cancer	0.00594	0.0412	CbGbCtD
Sunitinib—ABCB1—Dactinomycin—uterine cancer	0.00556	0.0386	CbGbCtD
Sunitinib—CYP3A5—Etoposide—uterine cancer	0.00482	0.0335	CbGbCtD
Sunitinib—CYP3A4—Progesterone—uterine cancer	0.0042	0.0292	CbGbCtD
Sunitinib—ABCB1—Etoposide—uterine cancer	0.00314	0.0218	CbGbCtD
Sunitinib—ABCB1—Doxorubicin—uterine cancer	0.00214	0.0149	CbGbCtD
Sunitinib—CYP3A4—Etoposide—uterine cancer	0.00188	0.0131	CbGbCtD
Sunitinib—CYP3A4—Doxorubicin—uterine cancer	0.00128	0.00891	CbGbCtD
Sunitinib—TLK2—Progesterone—Medroxyprogesterone Acetate—uterine cancer	0.000379	0.118	CbGdCrCtD
Sunitinib—STK24—Teniposide—Etoposide—uterine cancer	0.000368	0.114	CbGdCrCtD
Sunitinib—MAP4K4—Testosterone Propionate—Medroxyprogesterone Acetate—uterine cancer	0.000262	0.0812	CbGdCrCtD
Sunitinib—MAP4K4—Testosterone Propionate—Progesterone—uterine cancer	0.000228	0.0708	CbGdCrCtD
Sunitinib—PLK4—Teniposide—Etoposide—uterine cancer	0.000117	0.0364	CbGdCrCtD
Sunitinib—CSNK1E—Danazol—Progesterone—uterine cancer	0.000104	0.0323	CbGdCrCtD
Sunitinib—CHEK2—Podofilox—Etoposide—uterine cancer	0.000103	0.0321	CbGdCrCtD
Sunitinib—CHEK2—Teniposide—Etoposide—uterine cancer	0.000103	0.0321	CbGdCrCtD
Sunitinib—TYK2—female reproductive system—uterine cancer	0.000102	0.000815	CbGeAlD
Sunitinib—TAOK3—renal system—uterine cancer	0.000102	0.000813	CbGeAlD
Sunitinib—FYN—uterus—uterine cancer	0.000102	0.000813	CbGeAlD
Sunitinib—PTK2B—female gonad—uterine cancer	0.000101	0.00081	CbGeAlD
Sunitinib—CHEK2—lymph node—uterine cancer	0.000101	0.000808	CbGeAlD
Sunitinib—NUAK1—lymph node—uterine cancer	0.000101	0.000808	CbGeAlD
Sunitinib—FLT4—female gonad—uterine cancer	0.000101	0.000808	CbGeAlD
Sunitinib—PDGFRA—renal system—uterine cancer	0.000101	0.000808	CbGeAlD
Sunitinib—FLT1—mammalian vulva—uterine cancer	0.000101	0.000806	CbGeAlD
Sunitinib—PTK2B—vagina—uterine cancer	0.000101	0.000805	CbGeAlD
Sunitinib—IRAK1—female reproductive system—uterine cancer	0.000101	0.000804	CbGeAlD
Sunitinib—SNRK—lymph node—uterine cancer	0.0001	0.000802	CbGeAlD
Sunitinib—OXSR1—lymph node—uterine cancer	0.0001	0.000802	CbGeAlD
Sunitinib—INSR—lymph node—uterine cancer	0.0001	0.000802	CbGeAlD
Sunitinib—FGFR1—female gonad—uterine cancer	9.98e-05	0.000797	CbGeAlD
Sunitinib—CSNK1E—female gonad—uterine cancer	9.98e-05	0.000797	CbGeAlD
Sunitinib—EPHB6—mammalian vulva—uterine cancer	9.97e-05	0.000797	CbGeAlD
Sunitinib—YES1—endometrium—uterine cancer	9.96e-05	0.000796	CbGeAlD
Sunitinib—MAP4K5—uterus—uterine cancer	9.94e-05	0.000795	CbGeAlD
Sunitinib—CSNK1E—vagina—uterine cancer	9.91e-05	0.000792	CbGeAlD
Sunitinib—FGFR1—vagina—uterine cancer	9.91e-05	0.000792	CbGeAlD
Sunitinib—RPS6KA2—lymph node—uterine cancer	9.87e-05	0.000789	CbGeAlD
Sunitinib—STK38—lymph node—uterine cancer	9.87e-05	0.000789	CbGeAlD
Sunitinib—RPS6KB1—female reproductive system—uterine cancer	9.87e-05	0.000789	CbGeAlD
Sunitinib—TAOK3—endometrium—uterine cancer	9.84e-05	0.000786	CbGeAlD
Sunitinib—KDR—epithelium—uterine cancer	9.83e-05	0.000786	CbGeAlD
Sunitinib—IRAK4—female gonad—uterine cancer	9.82e-05	0.000785	CbGeAlD
Sunitinib—FGR—female reproductive system—uterine cancer	9.81e-05	0.000784	CbGeAlD
Sunitinib—AURKC—lymph node—uterine cancer	9.8e-05	0.000783	CbGeAlD
Sunitinib—AXL—female reproductive system—uterine cancer	9.77e-05	0.000781	CbGeAlD
Sunitinib—IRAK4—vagina—uterine cancer	9.76e-05	0.00078	CbGeAlD
Sunitinib—KDR—uterine cervix—uterine cancer	9.75e-05	0.000779	CbGeAlD
Sunitinib—MAP2K5—uterine cervix—uterine cancer	9.75e-05	0.000779	CbGeAlD
Sunitinib—PKN1—lymph node—uterine cancer	9.72e-05	0.000777	CbGeAlD
Sunitinib—CSNK1G2—lymph node—uterine cancer	9.72e-05	0.000777	CbGeAlD
Sunitinib—YES1—mammalian vulva—uterine cancer	9.64e-05	0.00077	CbGeAlD
Sunitinib—FLT1—uterus—uterine cancer	9.61e-05	0.000768	CbGeAlD
Sunitinib—MAP2K2—female gonad—uterine cancer	9.6e-05	0.000767	CbGeAlD
Sunitinib—ULK3—female gonad—uterine cancer	9.6e-05	0.000767	CbGeAlD
Sunitinib—PRPF4—lymph node—uterine cancer	9.58e-05	0.000766	CbGeAlD
Sunitinib—STK10—mammalian vulva—uterine cancer	9.55e-05	0.000763	CbGeAlD
Sunitinib—ULK3—vagina—uterine cancer	9.54e-05	0.000763	CbGeAlD
Sunitinib—MAP3K2—female gonad—uterine cancer	9.53e-05	0.000762	CbGeAlD
Sunitinib—TAOK3—mammalian vulva—uterine cancer	9.51e-05	0.00076	CbGeAlD
Sunitinib—CSF1R—uterine cervix—uterine cancer	9.51e-05	0.00076	CbGeAlD
Sunitinib—KDR—smooth muscle tissue—uterine cancer	9.47e-05	0.000757	CbGeAlD
Sunitinib—MAP3K7—female gonad—uterine cancer	9.44e-05	0.000755	CbGeAlD
Sunitinib—PRPF4B—lymph node—uterine cancer	9.44e-05	0.000755	CbGeAlD
Sunitinib—MAP3K7—vagina—uterine cancer	9.39e-05	0.00075	CbGeAlD
Sunitinib—TBK1—female gonad—uterine cancer	9.34e-05	0.000746	CbGeAlD
Sunitinib—FGFR2—female reproductive system—uterine cancer	9.32e-05	0.000745	CbGeAlD
Sunitinib—STK39—lymph node—uterine cancer	9.31e-05	0.000744	CbGeAlD
Sunitinib—KDR—decidua—uterine cancer	9.29e-05	0.000742	CbGeAlD
Sunitinib—MAP2K5—decidua—uterine cancer	9.29e-05	0.000742	CbGeAlD
Sunitinib—TBK1—vagina—uterine cancer	9.28e-05	0.000742	CbGeAlD
Sunitinib—TYK2—female gonad—uterine cancer	9.27e-05	0.000741	CbGeAlD
Sunitinib—JAK2—female reproductive system—uterine cancer	9.27e-05	0.000741	CbGeAlD
Sunitinib—CSF1R—smooth muscle tissue—uterine cancer	9.25e-05	0.000739	CbGeAlD
Sunitinib—TYK2—vagina—uterine cancer	9.22e-05	0.000737	CbGeAlD
Sunitinib—CSNK2A1—lymph node—uterine cancer	9.19e-05	0.000735	CbGeAlD
Sunitinib—YES1—uterus—uterine cancer	9.18e-05	0.000734	CbGeAlD
Sunitinib—IRAK1—female gonad—uterine cancer	9.15e-05	0.000732	CbGeAlD
Sunitinib—FYN—female reproductive system—uterine cancer	9.15e-05	0.000731	CbGeAlD
Sunitinib—KDR—renal system—uterine cancer	9.12e-05	0.000729	CbGeAlD
Sunitinib—STK10—uterus—uterine cancer	9.1e-05	0.000727	CbGeAlD
Sunitinib—MYLK—lymph node—uterine cancer	9.07e-05	0.000725	CbGeAlD
Sunitinib—CSF1R—decidua—uterine cancer	9.06e-05	0.000724	CbGeAlD
Sunitinib—TAOK3—uterus—uterine cancer	9.06e-05	0.000724	CbGeAlD
Sunitinib—PDGFRA—uterus—uterine cancer	9.01e-05	0.00072	CbGeAlD
Sunitinib—RPS6KB1—female gonad—uterine cancer	8.98e-05	0.000718	CbGeAlD
Sunitinib—PLK4—lymph node—uterine cancer	8.96e-05	0.000716	CbGeAlD
Sunitinib—DYRK1A—Daunorubicin—Epirubicin—uterine cancer	8.95e-05	0.0278	CbGdCrCtD
Sunitinib—DYRK1A—Doxorubicin—Epirubicin—uterine cancer	8.95e-05	0.0278	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Epirubicin—uterine cancer	8.95e-05	0.0278	CbGdCrCtD
Sunitinib—MAP3K3—female reproductive system—uterine cancer	8.94e-05	0.000714	CbGeAlD
Sunitinib—MAP4K5—female reproductive system—uterine cancer	8.94e-05	0.000714	CbGeAlD
Sunitinib—RPS6KB1—vagina—uterine cancer	8.93e-05	0.000713	CbGeAlD
Sunitinib—FGR—female gonad—uterine cancer	8.93e-05	0.000713	CbGeAlD
Sunitinib—STK4—lymph node—uterine cancer	8.91e-05	0.000712	CbGeAlD
Sunitinib—AXL—female gonad—uterine cancer	8.89e-05	0.000711	CbGeAlD
Sunitinib—FGR—vagina—uterine cancer	8.87e-05	0.000709	CbGeAlD
Sunitinib—AXL—vagina—uterine cancer	8.84e-05	0.000706	CbGeAlD
Sunitinib—KDR—endometrium—uterine cancer	8.82e-05	0.000705	CbGeAlD
Sunitinib—MAP2K5—endometrium—uterine cancer	8.82e-05	0.000705	CbGeAlD
Sunitinib—PHKG2—lymph node—uterine cancer	8.75e-05	0.000699	CbGeAlD
Sunitinib—KIT—epithelium—uterine cancer	8.71e-05	0.000696	CbGeAlD
Sunitinib—STK24—lymph node—uterine cancer	8.7e-05	0.000695	CbGeAlD
Sunitinib—FLT1—female reproductive system—uterine cancer	8.64e-05	0.000691	CbGeAlD
Sunitinib—KIT—uterine cervix—uterine cancer	8.64e-05	0.00069	CbGeAlD
Sunitinib—CSF1R—endometrium—uterine cancer	8.6e-05	0.000688	CbGeAlD
Sunitinib—DAPK2—lymph node—uterine cancer	8.6e-05	0.000687	CbGeAlD
Sunitinib—SLK—female gonad—uterine cancer	8.56e-05	0.000684	CbGeAlD
Sunitinib—KDR—mammalian vulva—uterine cancer	8.53e-05	0.000682	CbGeAlD
Sunitinib—MAP2K5—mammalian vulva—uterine cancer	8.53e-05	0.000682	CbGeAlD
Sunitinib—PDGFRB—epithelium—uterine cancer	8.51e-05	0.00068	CbGeAlD
Sunitinib—SLK—vagina—uterine cancer	8.51e-05	0.00068	CbGeAlD
Sunitinib—FGFR2—female gonad—uterine cancer	8.48e-05	0.000678	CbGeAlD
Sunitinib—STK16—lymph node—uterine cancer	8.46e-05	0.000676	CbGeAlD
Sunitinib—PDGFRB—uterine cervix—uterine cancer	8.44e-05	0.000674	CbGeAlD
Sunitinib—JAK2—female gonad—uterine cancer	8.44e-05	0.000674	CbGeAlD
Sunitinib—HIPK2—lymph node—uterine cancer	8.42e-05	0.000673	CbGeAlD
Sunitinib—HIPK3—lymph node—uterine cancer	8.42e-05	0.000673	CbGeAlD
Sunitinib—ALK—lymph node—uterine cancer	8.42e-05	0.000673	CbGeAlD
Sunitinib—KIT—smooth muscle tissue—uterine cancer	8.4e-05	0.000671	CbGeAlD
Sunitinib—JAK2—vagina—uterine cancer	8.39e-05	0.00067	CbGeAlD
Sunitinib—TNK1—lymph node—uterine cancer	8.33e-05	0.000666	CbGeAlD
Sunitinib—RIOK2—lymph node—uterine cancer	8.33e-05	0.000666	CbGeAlD
Sunitinib—CSF1R—mammalian vulva—uterine cancer	8.32e-05	0.000665	CbGeAlD
Sunitinib—FYN—female gonad—uterine cancer	8.32e-05	0.000665	CbGeAlD
Sunitinib—DYRK1A—Idarubicin—Doxorubicin—uterine cancer	8.28e-05	0.0257	CbGdCrCtD
Sunitinib—DYRK1A—Epirubicin—Doxorubicin—uterine cancer	8.28e-05	0.0257	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Doxorubicin—uterine cancer	8.28e-05	0.0257	CbGdCrCtD
Sunitinib—FYN—vagina—uterine cancer	8.27e-05	0.000661	CbGeAlD
Sunitinib—YES1—female reproductive system—uterine cancer	8.25e-05	0.00066	CbGeAlD
Sunitinib—MAP4K1—lymph node—uterine cancer	8.25e-05	0.000659	CbGeAlD
Sunitinib—KIT—decidua—uterine cancer	8.23e-05	0.000658	CbGeAlD
Sunitinib—PDGFRB—smooth muscle tissue—uterine cancer	8.2e-05	0.000655	CbGeAlD
Sunitinib—STK10—female reproductive system—uterine cancer	8.18e-05	0.000654	CbGeAlD
Sunitinib—TAOK3—female reproductive system—uterine cancer	8.15e-05	0.000651	CbGeAlD
Sunitinib—MAP4K5—female gonad—uterine cancer	8.13e-05	0.00065	CbGeAlD
Sunitinib—MAP3K3—female gonad—uterine cancer	8.13e-05	0.00065	CbGeAlD
Sunitinib—KDR—uterus—uterine cancer	8.12e-05	0.000649	CbGeAlD
Sunitinib—PDGFRA—female reproductive system—uterine cancer	8.1e-05	0.000647	CbGeAlD
Sunitinib—DAPK3—lymph node—uterine cancer	8.09e-05	0.000646	CbGeAlD
Sunitinib—MAP3K3—vagina—uterine cancer	8.08e-05	0.000646	CbGeAlD
Sunitinib—MAP4K5—vagina—uterine cancer	8.08e-05	0.000646	CbGeAlD
Sunitinib—KIT—renal system—uterine cancer	8.08e-05	0.000646	CbGeAlD
Sunitinib—PDGFRB—decidua—uterine cancer	8.04e-05	0.000642	CbGeAlD
Sunitinib—CLK2—lymph node—uterine cancer	8.01e-05	0.00064	CbGeAlD
Sunitinib—MAP4K2—lymph node—uterine cancer	7.97e-05	0.000637	CbGeAlD
Sunitinib—CSF1R—uterus—uterine cancer	7.93e-05	0.000634	CbGeAlD
Sunitinib—PDGFRB—renal system—uterine cancer	7.89e-05	0.000631	CbGeAlD
Sunitinib—STK3—lymph node—uterine cancer	7.87e-05	0.000629	CbGeAlD
Sunitinib—FLT1—female gonad—uterine cancer	7.86e-05	0.000628	CbGeAlD
Sunitinib—FLT1—vagina—uterine cancer	7.81e-05	0.000625	CbGeAlD
Sunitinib—KIT—endometrium—uterine cancer	7.81e-05	0.000624	CbGeAlD
Sunitinib—EPHB6—female gonad—uterine cancer	7.77e-05	0.000621	CbGeAlD
Sunitinib—PRPF4—Daunorubicin—Epirubicin—uterine cancer	7.73e-05	0.024	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Epirubicin—uterine cancer	7.73e-05	0.024	CbGdCrCtD
Sunitinib—EPHB6—vagina—uterine cancer	7.72e-05	0.000617	CbGeAlD
Sunitinib—PDGFRB—endometrium—uterine cancer	7.63e-05	0.00061	CbGeAlD
Sunitinib—DYRK1A—lymph node—uterine cancer	7.57e-05	0.000605	CbGeAlD
Sunitinib—KIT—mammalian vulva—uterine cancer	7.56e-05	0.000604	CbGeAlD
Sunitinib—Renal failure acute—Doxorubicin—uterine cancer	7.54e-05	0.000652	CcSEcCtD
Sunitinib—Pain in extremity—Epirubicin—uterine cancer	7.52e-05	0.000651	CcSEcCtD
Sunitinib—YES1—female gonad—uterine cancer	7.51e-05	0.0006	CbGeAlD
Sunitinib—Anaemia—Etoposide—uterine cancer	7.47e-05	0.000646	CcSEcCtD
Sunitinib—YES1—vagina—uterine cancer	7.46e-05	0.000597	CbGeAlD
Sunitinib—Gastrointestinal pain—Dactinomycin—uterine cancer	7.45e-05	0.000645	CcSEcCtD
Sunitinib—STK10—female gonad—uterine cancer	7.44e-05	0.000595	CbGeAlD
Sunitinib—Hot flush—Doxorubicin—uterine cancer	7.44e-05	0.000644	CcSEcCtD
Sunitinib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	7.43e-05	0.000643	CcSEcCtD
Sunitinib—TAOK3—female gonad—uterine cancer	7.41e-05	0.000593	CbGeAlD
Sunitinib—STK10—vagina—uterine cancer	7.4e-05	0.000591	CbGeAlD
Sunitinib—MERTK—lymph node—uterine cancer	7.4e-05	0.000591	CbGeAlD
Sunitinib—PDGFRB—mammalian vulva—uterine cancer	7.38e-05	0.00059	CbGeAlD
Sunitinib—Menopausal symptoms—Doxorubicin—uterine cancer	7.38e-05	0.000638	CcSEcCtD
Sunitinib—TAOK3—vagina—uterine cancer	7.37e-05	0.000589	CbGeAlD
Sunitinib—PDGFRA—female gonad—uterine cancer	7.37e-05	0.000589	CbGeAlD
Sunitinib—Rash—Medroxyprogesterone Acetate—uterine cancer	7.37e-05	0.000637	CcSEcCtD
Sunitinib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	7.36e-05	0.000637	CcSEcCtD
Sunitinib—CHEK2—Testosterone Propionate—Medroxyprogesterone Acetate—uterine cancer	7.34e-05	0.0228	CbGdCrCtD
Sunitinib—PDGFRA—vagina—uterine cancer	7.32e-05	0.000585	CbGeAlD
Sunitinib—Headache—Medroxyprogesterone Acetate—uterine cancer	7.32e-05	0.000633	CcSEcCtD
Sunitinib—Renal impairment—Doxorubicin—uterine cancer	7.31e-05	0.000633	CcSEcCtD
Sunitinib—KDR—female reproductive system—uterine cancer	7.3e-05	0.000584	CbGeAlD
Sunitinib—MAP2K5—female reproductive system—uterine cancer	7.3e-05	0.000584	CbGeAlD
Sunitinib—Dermatitis bullous—Doxorubicin—uterine cancer	7.28e-05	0.00063	CcSEcCtD
Sunitinib—Face oedema—Epirubicin—uterine cancer	7.26e-05	0.000628	CcSEcCtD
Sunitinib—MAP4K4—lymph node—uterine cancer	7.26e-05	0.00058	CbGeAlD
Sunitinib—Leukopenia—Etoposide—uterine cancer	7.23e-05	0.000626	CcSEcCtD
Sunitinib—NUAK2—lymph node—uterine cancer	7.21e-05	0.000576	CbGeAlD
Sunitinib—Abdominal pain—Dactinomycin—uterine cancer	7.2e-05	0.000623	CcSEcCtD
Sunitinib—Body temperature increased—Dactinomycin—uterine cancer	7.2e-05	0.000623	CcSEcCtD
Sunitinib—KIT—uterus—uterine cancer	7.2e-05	0.000575	CbGeAlD
Sunitinib—FLT3—lymph node—uterine cancer	7.16e-05	0.000572	CbGeAlD
Sunitinib—MAP3K12—lymph node—uterine cancer	7.16e-05	0.000572	CbGeAlD
Sunitinib—PRPF4—Idarubicin—Doxorubicin—uterine cancer	7.15e-05	0.0222	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Doxorubicin—uterine cancer	7.15e-05	0.0222	CbGdCrCtD
Sunitinib—Cardiac failure—Doxorubicin—uterine cancer	7.13e-05	0.000617	CcSEcCtD
Sunitinib—Hypoglycaemia—Doxorubicin—uterine cancer	7.13e-05	0.000617	CcSEcCtD
Sunitinib—CSF1R—female reproductive system—uterine cancer	7.13e-05	0.00057	CbGeAlD
Sunitinib—Cerebrovascular accident—Doxorubicin—uterine cancer	7.1e-05	0.000614	CcSEcCtD
Sunitinib—RPS6KA3—lymph node—uterine cancer	7.06e-05	0.000564	CbGeAlD
Sunitinib—Cough—Etoposide—uterine cancer	7.05e-05	0.00061	CcSEcCtD
Sunitinib—Blood creatinine increased—Epirubicin—uterine cancer	7.05e-05	0.00061	CcSEcCtD
Sunitinib—PDGFRB—uterus—uterine cancer	7.03e-05	0.000562	CbGeAlD
Sunitinib—MAP2K1—lymph node—uterine cancer	7.01e-05	0.00056	CbGeAlD
Sunitinib—Convulsion—Etoposide—uterine cancer	7e-05	0.000606	CcSEcCtD
Sunitinib—Dehydration—Epirubicin—uterine cancer	7e-05	0.000605	CcSEcCtD
Sunitinib—Hyponatraemia—Doxorubicin—uterine cancer	6.99e-05	0.000604	CcSEcCtD
Sunitinib—Hypertension—Etoposide—uterine cancer	6.98e-05	0.000604	CcSEcCtD
Sunitinib—Pain in extremity—Doxorubicin—uterine cancer	6.96e-05	0.000602	CcSEcCtD
Sunitinib—Liver function test abnormal—Epirubicin—uterine cancer	6.94e-05	0.000601	CcSEcCtD
Sunitinib—Nausea—Medroxyprogesterone Acetate—uterine cancer	6.94e-05	0.0006	CcSEcCtD
Sunitinib—CSNK1A1—lymph node—uterine cancer	6.92e-05	0.000553	CbGeAlD
Sunitinib—Dry skin—Epirubicin—uterine cancer	6.89e-05	0.000596	CcSEcCtD
Sunitinib—Chest pain—Etoposide—uterine cancer	6.88e-05	0.000595	CcSEcCtD
Sunitinib—CLK1—lymph node—uterine cancer	6.88e-05	0.00055	CbGeAlD
Sunitinib—Abdominal pain upper—Epirubicin—uterine cancer	6.87e-05	0.000594	CcSEcCtD
Sunitinib—PRPF4—Norethindrone—Progesterone—uterine cancer	6.87e-05	0.0213	CbGdCrCtD
Sunitinib—KCNH2—myometrium—uterine cancer	6.85e-05	0.000548	CbGeAlD
Sunitinib—Hypokalaemia—Epirubicin—uterine cancer	6.85e-05	0.000592	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	6.83e-05	0.000591	CcSEcCtD
Sunitinib—Toxic epidermal necrolysis—Epirubicin—uterine cancer	6.77e-05	0.000586	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	6.77e-05	0.000586	CcSEcCtD
Sunitinib—CAMK2G—lymph node—uterine cancer	6.75e-05	0.000539	CbGeAlD
Sunitinib—BMP2K—lymph node—uterine cancer	6.75e-05	0.000539	CbGeAlD
Sunitinib—Nasopharyngitis—Epirubicin—uterine cancer	6.73e-05	0.000582	CcSEcCtD
Sunitinib—Face oedema—Doxorubicin—uterine cancer	6.72e-05	0.000581	CcSEcCtD
Sunitinib—Hypersensitivity—Dactinomycin—uterine cancer	6.71e-05	0.000581	CcSEcCtD
Sunitinib—LRRK2—lymph node—uterine cancer	6.69e-05	0.000535	CbGeAlD
Sunitinib—MAP2K5—female gonad—uterine cancer	6.65e-05	0.000531	CbGeAlD
Sunitinib—KDR—female gonad—uterine cancer	6.65e-05	0.000531	CbGeAlD
Sunitinib—Muscular weakness—Epirubicin—uterine cancer	6.63e-05	0.000574	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Epirubicin—uterine cancer	6.63e-05	0.000574	CcSEcCtD
Sunitinib—KDR—vagina—uterine cancer	6.61e-05	0.000528	CbGeAlD
Sunitinib—MAP2K5—vagina—uterine cancer	6.61e-05	0.000528	CbGeAlD
Sunitinib—PRKAA1—lymph node—uterine cancer	6.59e-05	0.000527	CbGeAlD
Sunitinib—Infection—Etoposide—uterine cancer	6.55e-05	0.000567	CcSEcCtD
Sunitinib—Abdominal distension—Epirubicin—uterine cancer	6.54e-05	0.000566	CcSEcCtD
Sunitinib—Asthenia—Dactinomycin—uterine cancer	6.54e-05	0.000566	CcSEcCtD
Sunitinib—Blood creatinine increased—Doxorubicin—uterine cancer	6.52e-05	0.000564	CcSEcCtD
Sunitinib—PTK2B—lymph node—uterine cancer	6.52e-05	0.000521	CbGeAlD
Sunitinib—Dysphagia—Epirubicin—uterine cancer	6.5e-05	0.000562	CcSEcCtD
Sunitinib—FLT4—lymph node—uterine cancer	6.5e-05	0.00052	CbGeAlD
Sunitinib—CSF1R—female gonad—uterine cancer	6.49e-05	0.000518	CbGeAlD
Sunitinib—KIT—female reproductive system—uterine cancer	6.47e-05	0.000517	CbGeAlD
Sunitinib—Dehydration—Doxorubicin—uterine cancer	6.47e-05	0.00056	CcSEcCtD
Sunitinib—Thrombocytopenia—Etoposide—uterine cancer	6.46e-05	0.000559	CcSEcCtD
Sunitinib—CSF1R—vagina—uterine cancer	6.45e-05	0.000515	CbGeAlD
Sunitinib—Liver function test abnormal—Doxorubicin—uterine cancer	6.43e-05	0.000556	CcSEcCtD
Sunitinib—CSNK1E—lymph node—uterine cancer	6.41e-05	0.000513	CbGeAlD
Sunitinib—FGFR1—lymph node—uterine cancer	6.41e-05	0.000513	CbGeAlD
Sunitinib—Skin disorder—Etoposide—uterine cancer	6.41e-05	0.000554	CcSEcCtD
Sunitinib—CHEK2—Testosterone Propionate—Progesterone—uterine cancer	6.4e-05	0.0199	CbGdCrCtD
Sunitinib—Dry skin—Doxorubicin—uterine cancer	6.38e-05	0.000552	CcSEcCtD
Sunitinib—Pancreatitis—Epirubicin—uterine cancer	6.37e-05	0.000551	CcSEcCtD
Sunitinib—Abdominal pain upper—Doxorubicin—uterine cancer	6.36e-05	0.00055	CcSEcCtD
Sunitinib—Hypokalaemia—Doxorubicin—uterine cancer	6.33e-05	0.000548	CcSEcCtD
Sunitinib—PDGFRB—female reproductive system—uterine cancer	6.32e-05	0.000505	CbGeAlD
Sunitinib—IRAK4—lymph node—uterine cancer	6.31e-05	0.000505	CbGeAlD
Sunitinib—Anorexia—Etoposide—uterine cancer	6.29e-05	0.000544	CcSEcCtD
Sunitinib—ABCC4—renal system—uterine cancer	6.29e-05	0.000502	CbGeAlD
Sunitinib—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	6.27e-05	0.000542	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	6.27e-05	0.000542	CcSEcCtD
Sunitinib—Bronchitis—Epirubicin—uterine cancer	6.25e-05	0.000541	CcSEcCtD
Sunitinib—Diarrhoea—Dactinomycin—uterine cancer	6.23e-05	0.000539	CcSEcCtD
Sunitinib—Nasopharyngitis—Doxorubicin—uterine cancer	6.22e-05	0.000538	CcSEcCtD
Sunitinib—Pancytopenia—Epirubicin—uterine cancer	6.17e-05	0.000534	CcSEcCtD
Sunitinib—MAP2K2—lymph node—uterine cancer	6.17e-05	0.000493	CbGeAlD
Sunitinib—ULK3—lymph node—uterine cancer	6.17e-05	0.000493	CbGeAlD
Sunitinib—Muscular weakness—Doxorubicin—uterine cancer	6.14e-05	0.000531	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	6.14e-05	0.000531	CcSEcCtD
Sunitinib—MAP3K2—lymph node—uterine cancer	6.13e-05	0.00049	CbGeAlD
Sunitinib—PLK4—Idarubicin—Epirubicin—uterine cancer	6.12e-05	0.019	CbGdCrCtD
Sunitinib—PLK4—Doxorubicin—Epirubicin—uterine cancer	6.12e-05	0.019	CbGdCrCtD
Sunitinib—ABCG2—myometrium—uterine cancer	6.09e-05	0.000487	CbGeAlD
Sunitinib—ABCC2—renal system—uterine cancer	6.08e-05	0.000486	CbGeAlD
Sunitinib—Neutropenia—Epirubicin—uterine cancer	6.08e-05	0.000526	CcSEcCtD
Sunitinib—MAP3K7—lymph node—uterine cancer	6.07e-05	0.000485	CbGeAlD
Sunitinib—Abdominal distension—Doxorubicin—uterine cancer	6.06e-05	0.000524	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Epirubicin—uterine cancer	6.04e-05	0.000523	CcSEcCtD
Sunitinib—Dysphagia—Doxorubicin—uterine cancer	6.02e-05	0.00052	CcSEcCtD
Sunitinib—TBK1—lymph node—uterine cancer	6e-05	0.00048	CbGeAlD
Sunitinib—TYK2—lymph node—uterine cancer	5.96e-05	0.000476	CbGeAlD
Sunitinib—Paraesthesia—Etoposide—uterine cancer	5.92e-05	0.000512	CcSEcCtD
Sunitinib—Pancreatitis—Doxorubicin—uterine cancer	5.9e-05	0.00051	CcSEcCtD
Sunitinib—KIT—female gonad—uterine cancer	5.89e-05	0.000471	CbGeAlD
Sunitinib—IRAK1—lymph node—uterine cancer	5.88e-05	0.00047	CbGeAlD
Sunitinib—Weight decreased—Epirubicin—uterine cancer	5.88e-05	0.000509	CcSEcCtD
Sunitinib—Dyspnoea—Etoposide—uterine cancer	5.88e-05	0.000509	CcSEcCtD
Sunitinib—Hyperglycaemia—Epirubicin—uterine cancer	5.86e-05	0.000507	CcSEcCtD
Sunitinib—KIT—vagina—uterine cancer	5.85e-05	0.000468	CbGeAlD
Sunitinib—Pneumonia—Epirubicin—uterine cancer	5.83e-05	0.000504	CcSEcCtD
Sunitinib—Infestation NOS—Epirubicin—uterine cancer	5.8e-05	0.000501	CcSEcCtD
Sunitinib—Infestation—Epirubicin—uterine cancer	5.8e-05	0.000501	CcSEcCtD
Sunitinib—Vomiting—Dactinomycin—uterine cancer	5.79e-05	0.000501	CcSEcCtD
Sunitinib—Bronchitis—Doxorubicin—uterine cancer	5.79e-05	0.0005	CcSEcCtD
Sunitinib—RPS6KB1—lymph node—uterine cancer	5.77e-05	0.000461	CbGeAlD
Sunitinib—PDGFRB—female gonad—uterine cancer	5.75e-05	0.00046	CbGeAlD
Sunitinib—Stevens-Johnson syndrome—Epirubicin—uterine cancer	5.75e-05	0.000497	CcSEcCtD
Sunitinib—Rash—Dactinomycin—uterine cancer	5.75e-05	0.000497	CcSEcCtD
Sunitinib—RET—lymph node—uterine cancer	5.74e-05	0.000459	CbGeAlD
Sunitinib—FGR—lymph node—uterine cancer	5.74e-05	0.000459	CbGeAlD
Sunitinib—Decreased appetite—Etoposide—uterine cancer	5.73e-05	0.000496	CcSEcCtD
Sunitinib—PDGFRB—vagina—uterine cancer	5.72e-05	0.000457	CbGeAlD
Sunitinib—AXL—lymph node—uterine cancer	5.72e-05	0.000457	CbGeAlD
Sunitinib—Pancytopenia—Doxorubicin—uterine cancer	5.71e-05	0.000494	CcSEcCtD
Sunitinib—Renal failure—Epirubicin—uterine cancer	5.7e-05	0.000493	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Etoposide—uterine cancer	5.69e-05	0.000493	CcSEcCtD
Sunitinib—Fatigue—Etoposide—uterine cancer	5.69e-05	0.000492	CcSEcCtD
Sunitinib—Neuropathy peripheral—Epirubicin—uterine cancer	5.68e-05	0.000491	CcSEcCtD
Sunitinib—PLK4—Idarubicin—Doxorubicin—uterine cancer	5.66e-05	0.0176	CbGdCrCtD
Sunitinib—PLK4—Epirubicin—Doxorubicin—uterine cancer	5.66e-05	0.0176	CbGdCrCtD
Sunitinib—Stomatitis—Epirubicin—uterine cancer	5.65e-05	0.000489	CcSEcCtD
Sunitinib—Pain—Etoposide—uterine cancer	5.64e-05	0.000488	CcSEcCtD
Sunitinib—Constipation—Etoposide—uterine cancer	5.64e-05	0.000488	CcSEcCtD
Sunitinib—Urinary tract infection—Epirubicin—uterine cancer	5.63e-05	0.000487	CcSEcCtD
Sunitinib—Neutropenia—Doxorubicin—uterine cancer	5.62e-05	0.000487	CcSEcCtD
Sunitinib—ABCC4—uterus—uterine cancer	5.6e-05	0.000448	CbGeAlD
Sunitinib—Upper respiratory tract infection—Doxorubicin—uterine cancer	5.59e-05	0.000484	CcSEcCtD
Sunitinib—SLK—lymph node—uterine cancer	5.5e-05	0.00044	CbGeAlD
Sunitinib—Hepatobiliary disease—Epirubicin—uterine cancer	5.48e-05	0.000474	CcSEcCtD
Sunitinib—Epistaxis—Epirubicin—uterine cancer	5.47e-05	0.000473	CcSEcCtD
Sunitinib—PRPF4—Levonorgestrel—Progesterone—uterine cancer	5.47e-05	0.017	CbGdCrCtD
Sunitinib—Weight decreased—Doxorubicin—uterine cancer	5.44e-05	0.000471	CcSEcCtD
Sunitinib—Hyperglycaemia—Doxorubicin—uterine cancer	5.43e-05	0.000469	CcSEcCtD
Sunitinib—JAK2—lymph node—uterine cancer	5.42e-05	0.000433	CbGeAlD
Sunitinib—Nausea—Dactinomycin—uterine cancer	5.41e-05	0.000468	CcSEcCtD
Sunitinib—Pneumonia—Doxorubicin—uterine cancer	5.39e-05	0.000467	CcSEcCtD
Sunitinib—Gastrointestinal pain—Etoposide—uterine cancer	5.39e-05	0.000467	CcSEcCtD
Sunitinib—CHEK2—Doxorubicin—Epirubicin—uterine cancer	5.39e-05	0.0167	CbGdCrCtD
Sunitinib—Infestation NOS—Doxorubicin—uterine cancer	5.36e-05	0.000464	CcSEcCtD
Sunitinib—Infestation—Doxorubicin—uterine cancer	5.36e-05	0.000464	CcSEcCtD
Sunitinib—FYN—lymph node—uterine cancer	5.35e-05	0.000428	CbGeAlD
Sunitinib—KCNH2—uterine cervix—uterine cancer	5.33e-05	0.000426	CbGeAlD
Sunitinib—CHEK2—Danazol—Progesterone—uterine cancer	5.32e-05	0.0165	CbGdCrCtD
Sunitinib—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	5.32e-05	0.00046	CcSEcCtD
Sunitinib—Bradycardia—Epirubicin—uterine cancer	5.3e-05	0.000458	CcSEcCtD
Sunitinib—Renal failure—Doxorubicin—uterine cancer	5.27e-05	0.000456	CcSEcCtD
Sunitinib—Neuropathy peripheral—Doxorubicin—uterine cancer	5.26e-05	0.000455	CcSEcCtD
Sunitinib—Haemoglobin—Epirubicin—uterine cancer	5.23e-05	0.000452	CcSEcCtD
Sunitinib—Stomatitis—Doxorubicin—uterine cancer	5.23e-05	0.000452	CcSEcCtD
Sunitinib—MAP3K3—lymph node—uterine cancer	5.23e-05	0.000418	CbGeAlD
Sunitinib—MAP4K5—lymph node—uterine cancer	5.23e-05	0.000418	CbGeAlD
Sunitinib—Body temperature increased—Etoposide—uterine cancer	5.21e-05	0.000451	CcSEcCtD
Sunitinib—Abdominal pain—Etoposide—uterine cancer	5.21e-05	0.000451	CcSEcCtD
Sunitinib—Urinary tract infection—Doxorubicin—uterine cancer	5.21e-05	0.000451	CcSEcCtD
Sunitinib—Hepatitis—Epirubicin—uterine cancer	5.2e-05	0.00045	CcSEcCtD
Sunitinib—Haemorrhage—Epirubicin—uterine cancer	5.2e-05	0.00045	CcSEcCtD
Sunitinib—Hypoaesthesia—Epirubicin—uterine cancer	5.18e-05	0.000448	CcSEcCtD
Sunitinib—Urinary tract disorder—Epirubicin—uterine cancer	5.14e-05	0.000445	CcSEcCtD
Sunitinib—Oedema peripheral—Epirubicin—uterine cancer	5.13e-05	0.000443	CcSEcCtD
Sunitinib—Connective tissue disorder—Epirubicin—uterine cancer	5.11e-05	0.000442	CcSEcCtD
Sunitinib—Urethral disorder—Epirubicin—uterine cancer	5.1e-05	0.000441	CcSEcCtD
Sunitinib—Hepatobiliary disease—Doxorubicin—uterine cancer	5.07e-05	0.000439	CcSEcCtD
Sunitinib—Epistaxis—Doxorubicin—uterine cancer	5.06e-05	0.000438	CcSEcCtD
Sunitinib—FLT1—lymph node—uterine cancer	5.05e-05	0.000404	CbGeAlD
Sunitinib—ABCC4—female reproductive system—uterine cancer	5.03e-05	0.000402	CbGeAlD
Sunitinib—EPHB6—lymph node—uterine cancer	5e-05	0.000399	CbGeAlD
Sunitinib—CHEK2—Epirubicin—Doxorubicin—uterine cancer	4.99e-05	0.0155	CbGdCrCtD
Sunitinib—KCNH2—renal system—uterine cancer	4.99e-05	0.000399	CbGeAlD
Sunitinib—Erythema multiforme—Epirubicin—uterine cancer	4.92e-05	0.000426	CcSEcCtD
Sunitinib—Bradycardia—Doxorubicin—uterine cancer	4.9e-05	0.000424	CcSEcCtD
Sunitinib—ABCC2—female reproductive system—uterine cancer	4.87e-05	0.000389	CbGeAlD
Sunitinib—Eye disorder—Epirubicin—uterine cancer	4.86e-05	0.000421	CcSEcCtD
Sunitinib—Hypersensitivity—Etoposide—uterine cancer	4.86e-05	0.00042	CcSEcCtD
Sunitinib—Haemoglobin—Doxorubicin—uterine cancer	4.84e-05	0.000419	CcSEcCtD
Sunitinib—Cardiac disorder—Epirubicin—uterine cancer	4.83e-05	0.000418	CcSEcCtD
Sunitinib—Flushing—Epirubicin—uterine cancer	4.83e-05	0.000418	CcSEcCtD
Sunitinib—YES1—lymph node—uterine cancer	4.83e-05	0.000386	CbGeAlD
Sunitinib—KCNH2—endometrium—uterine cancer	4.82e-05	0.000385	CbGeAlD
Sunitinib—Haemorrhage—Doxorubicin—uterine cancer	4.81e-05	0.000416	CcSEcCtD
Sunitinib—Hepatitis—Doxorubicin—uterine cancer	4.81e-05	0.000416	CcSEcCtD
Sunitinib—CHEK2—Norethindrone—Progesterone—uterine cancer	4.79e-05	0.0149	CbGdCrCtD
Sunitinib—Hypoaesthesia—Doxorubicin—uterine cancer	4.79e-05	0.000414	CcSEcCtD
Sunitinib—STK10—lymph node—uterine cancer	4.78e-05	0.000382	CbGeAlD
Sunitinib—TAOK3—lymph node—uterine cancer	4.77e-05	0.000381	CbGeAlD
Sunitinib—Urinary tract disorder—Doxorubicin—uterine cancer	4.75e-05	0.000411	CcSEcCtD
Sunitinib—Oedema peripheral—Doxorubicin—uterine cancer	4.74e-05	0.00041	CcSEcCtD
Sunitinib—ABCG2—uterine cervix—uterine cancer	4.74e-05	0.000379	CbGeAlD
Sunitinib—PDGFRA—lymph node—uterine cancer	4.74e-05	0.000379	CbGeAlD
Sunitinib—Asthenia—Etoposide—uterine cancer	4.73e-05	0.000409	CcSEcCtD
Sunitinib—Connective tissue disorder—Doxorubicin—uterine cancer	4.73e-05	0.000409	CcSEcCtD
Sunitinib—Angiopathy—Epirubicin—uterine cancer	4.72e-05	0.000408	CcSEcCtD
Sunitinib—Urethral disorder—Doxorubicin—uterine cancer	4.72e-05	0.000408	CcSEcCtD
Sunitinib—Immune system disorder—Epirubicin—uterine cancer	4.7e-05	0.000407	CcSEcCtD
Sunitinib—Mediastinal disorder—Epirubicin—uterine cancer	4.69e-05	0.000406	CcSEcCtD
Sunitinib—Chills—Epirubicin—uterine cancer	4.67e-05	0.000404	CcSEcCtD
Sunitinib—Pruritus—Etoposide—uterine cancer	4.67e-05	0.000404	CcSEcCtD
Sunitinib—Arrhythmia—Epirubicin—uterine cancer	4.65e-05	0.000402	CcSEcCtD
Sunitinib—Alopecia—Epirubicin—uterine cancer	4.6e-05	0.000398	CcSEcCtD
Sunitinib—ABCC4—female gonad—uterine cancer	4.58e-05	0.000366	CbGeAlD
Sunitinib—Mental disorder—Epirubicin—uterine cancer	4.56e-05	0.000394	CcSEcCtD
Sunitinib—Erythema multiforme—Doxorubicin—uterine cancer	4.55e-05	0.000394	CcSEcCtD
Sunitinib—Erythema—Epirubicin—uterine cancer	4.53e-05	0.000392	CcSEcCtD
Sunitinib—Malnutrition—Epirubicin—uterine cancer	4.53e-05	0.000392	CcSEcCtD
Sunitinib—ABCG2—decidua—uterine cancer	4.52e-05	0.000361	CbGeAlD
Sunitinib—Diarrhoea—Etoposide—uterine cancer	4.51e-05	0.00039	CcSEcCtD
Sunitinib—Eye disorder—Doxorubicin—uterine cancer	4.5e-05	0.000389	CcSEcCtD
Sunitinib—Cardiac disorder—Doxorubicin—uterine cancer	4.47e-05	0.000387	CcSEcCtD
Sunitinib—Flushing—Doxorubicin—uterine cancer	4.47e-05	0.000387	CcSEcCtD
Sunitinib—Flatulence—Epirubicin—uterine cancer	4.46e-05	0.000386	CcSEcCtD
Sunitinib—KCNH2—uterus—uterine cancer	4.44e-05	0.000355	CbGeAlD
Sunitinib—Dysgeusia—Epirubicin—uterine cancer	4.44e-05	0.000384	CcSEcCtD
Sunitinib—CYP3A5—uterine cervix—uterine cancer	4.4e-05	0.000352	CbGeAlD
Sunitinib—Back pain—Epirubicin—uterine cancer	4.38e-05	0.000379	CcSEcCtD
Sunitinib—Angiopathy—Doxorubicin—uterine cancer	4.37e-05	0.000378	CcSEcCtD
Sunitinib—Dizziness—Etoposide—uterine cancer	4.36e-05	0.000377	CcSEcCtD
Sunitinib—Muscle spasms—Epirubicin—uterine cancer	4.36e-05	0.000377	CcSEcCtD
Sunitinib—Immune system disorder—Doxorubicin—uterine cancer	4.35e-05	0.000376	CcSEcCtD
Sunitinib—Mediastinal disorder—Doxorubicin—uterine cancer	4.34e-05	0.000375	CcSEcCtD
Sunitinib—Chills—Doxorubicin—uterine cancer	4.32e-05	0.000374	CcSEcCtD
Sunitinib—Arrhythmia—Doxorubicin—uterine cancer	4.3e-05	0.000372	CcSEcCtD
Sunitinib—ABCG2—endometrium—uterine cancer	4.29e-05	0.000343	CbGeAlD
Sunitinib—KDR—lymph node—uterine cancer	4.27e-05	0.000341	CbGeAlD
Sunitinib—MAP2K5—lymph node—uterine cancer	4.27e-05	0.000341	CbGeAlD
Sunitinib—Alopecia—Doxorubicin—uterine cancer	4.25e-05	0.000368	CcSEcCtD
Sunitinib—Mental disorder—Doxorubicin—uterine cancer	4.22e-05	0.000365	CcSEcCtD
Sunitinib—Vomiting—Etoposide—uterine cancer	4.19e-05	0.000363	CcSEcCtD
Sunitinib—Erythema—Doxorubicin—uterine cancer	4.19e-05	0.000363	CcSEcCtD
Sunitinib—Malnutrition—Doxorubicin—uterine cancer	4.19e-05	0.000363	CcSEcCtD
Sunitinib—Anaemia—Epirubicin—uterine cancer	4.19e-05	0.000362	CcSEcCtD
Sunitinib—CSF1R—lymph node—uterine cancer	4.17e-05	0.000333	CbGeAlD
Sunitinib—Rash—Etoposide—uterine cancer	4.16e-05	0.00036	CcSEcCtD
Sunitinib—Dermatitis—Etoposide—uterine cancer	4.15e-05	0.000359	CcSEcCtD
Sunitinib—ABCG2—mammalian vulva—uterine cancer	4.15e-05	0.000332	CbGeAlD
Sunitinib—Headache—Etoposide—uterine cancer	4.13e-05	0.000357	CcSEcCtD
Sunitinib—Flatulence—Doxorubicin—uterine cancer	4.13e-05	0.000357	CcSEcCtD
Sunitinib—CYP3A5—renal system—uterine cancer	4.12e-05	0.000329	CbGeAlD
Sunitinib—Dysgeusia—Doxorubicin—uterine cancer	4.1e-05	0.000355	CcSEcCtD
Sunitinib—Leukopenia—Epirubicin—uterine cancer	4.05e-05	0.000351	CcSEcCtD
Sunitinib—Back pain—Doxorubicin—uterine cancer	4.05e-05	0.000351	CcSEcCtD
Sunitinib—Muscle spasms—Doxorubicin—uterine cancer	4.03e-05	0.000349	CcSEcCtD
Sunitinib—KCNH2—female reproductive system—uterine cancer	3.99e-05	0.000319	CbGeAlD
Sunitinib—Cough—Epirubicin—uterine cancer	3.95e-05	0.000342	CcSEcCtD
Sunitinib—ABCG2—uterus—uterine cancer	3.95e-05	0.000316	CbGeAlD
Sunitinib—Convulsion—Epirubicin—uterine cancer	3.92e-05	0.000339	CcSEcCtD
Sunitinib—Nausea—Etoposide—uterine cancer	3.92e-05	0.000339	CcSEcCtD
Sunitinib—Hypertension—Epirubicin—uterine cancer	3.91e-05	0.000338	CcSEcCtD
Sunitinib—Anaemia—Doxorubicin—uterine cancer	3.87e-05	0.000335	CcSEcCtD
Sunitinib—Arthralgia—Epirubicin—uterine cancer	3.86e-05	0.000334	CcSEcCtD
Sunitinib—Chest pain—Epirubicin—uterine cancer	3.86e-05	0.000334	CcSEcCtD
Sunitinib—Myalgia—Epirubicin—uterine cancer	3.86e-05	0.000334	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	3.83e-05	0.000331	CcSEcCtD
Sunitinib—CHEK2—Levonorgestrel—Progesterone—uterine cancer	3.81e-05	0.0118	CbGdCrCtD
Sunitinib—KIT—lymph node—uterine cancer	3.79e-05	0.000303	CbGeAlD
Sunitinib—Dry mouth—Epirubicin—uterine cancer	3.77e-05	0.000326	CcSEcCtD
Sunitinib—Leukopenia—Doxorubicin—uterine cancer	3.75e-05	0.000325	CcSEcCtD
Sunitinib—PDGFRB—lymph node—uterine cancer	3.7e-05	0.000296	CbGeAlD
Sunitinib—Oedema—Epirubicin—uterine cancer	3.7e-05	0.00032	CcSEcCtD
Sunitinib—Infection—Epirubicin—uterine cancer	3.67e-05	0.000318	CcSEcCtD
Sunitinib—Cough—Doxorubicin—uterine cancer	3.66e-05	0.000316	CcSEcCtD
Sunitinib—Shock—Epirubicin—uterine cancer	3.64e-05	0.000315	CcSEcCtD
Sunitinib—KCNH2—female gonad—uterine cancer	3.63e-05	0.00029	CbGeAlD
Sunitinib—Convulsion—Doxorubicin—uterine cancer	3.63e-05	0.000314	CcSEcCtD
Sunitinib—Nervous system disorder—Epirubicin—uterine cancer	3.63e-05	0.000314	CcSEcCtD
Sunitinib—Thrombocytopenia—Epirubicin—uterine cancer	3.62e-05	0.000313	CcSEcCtD
Sunitinib—Hypertension—Doxorubicin—uterine cancer	3.62e-05	0.000313	CcSEcCtD
Sunitinib—KCNH2—vagina—uterine cancer	3.61e-05	0.000289	CbGeAlD
Sunitinib—Skin disorder—Epirubicin—uterine cancer	3.59e-05	0.000311	CcSEcCtD
Sunitinib—Chest pain—Doxorubicin—uterine cancer	3.57e-05	0.000309	CcSEcCtD
Sunitinib—Myalgia—Doxorubicin—uterine cancer	3.57e-05	0.000309	CcSEcCtD
Sunitinib—Arthralgia—Doxorubicin—uterine cancer	3.57e-05	0.000309	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	3.54e-05	0.000307	CcSEcCtD
Sunitinib—Anorexia—Epirubicin—uterine cancer	3.52e-05	0.000305	CcSEcCtD
Sunitinib—Dry mouth—Doxorubicin—uterine cancer	3.49e-05	0.000302	CcSEcCtD
Sunitinib—Oedema—Doxorubicin—uterine cancer	3.42e-05	0.000296	CcSEcCtD
Sunitinib—Infection—Doxorubicin—uterine cancer	3.4e-05	0.000294	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Epirubicin—uterine cancer	3.37e-05	0.000291	CcSEcCtD
Sunitinib—Shock—Doxorubicin—uterine cancer	3.37e-05	0.000291	CcSEcCtD
Sunitinib—Nervous system disorder—Doxorubicin—uterine cancer	3.35e-05	0.00029	CcSEcCtD
Sunitinib—Thrombocytopenia—Doxorubicin—uterine cancer	3.35e-05	0.00029	CcSEcCtD
Sunitinib—Insomnia—Epirubicin—uterine cancer	3.34e-05	0.000289	CcSEcCtD
Sunitinib—Skin disorder—Doxorubicin—uterine cancer	3.32e-05	0.000287	CcSEcCtD
Sunitinib—Paraesthesia—Epirubicin—uterine cancer	3.32e-05	0.000287	CcSEcCtD
Sunitinib—Dyspnoea—Epirubicin—uterine cancer	3.3e-05	0.000285	CcSEcCtD
Sunitinib—Anorexia—Doxorubicin—uterine cancer	3.26e-05	0.000282	CcSEcCtD
Sunitinib—Dyspepsia—Epirubicin—uterine cancer	3.25e-05	0.000281	CcSEcCtD
Sunitinib—ABCG2—female gonad—uterine cancer	3.23e-05	0.000258	CbGeAlD
Sunitinib—Decreased appetite—Epirubicin—uterine cancer	3.21e-05	0.000278	CcSEcCtD
Sunitinib—ABCG2—vagina—uterine cancer	3.21e-05	0.000257	CbGeAlD
Sunitinib—Gastrointestinal disorder—Epirubicin—uterine cancer	3.19e-05	0.000276	CcSEcCtD
Sunitinib—Fatigue—Epirubicin—uterine cancer	3.19e-05	0.000276	CcSEcCtD
Sunitinib—Constipation—Epirubicin—uterine cancer	3.16e-05	0.000273	CcSEcCtD
Sunitinib—Pain—Epirubicin—uterine cancer	3.16e-05	0.000273	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	3.12e-05	0.00027	CcSEcCtD
Sunitinib—Insomnia—Doxorubicin—uterine cancer	3.09e-05	0.000268	CcSEcCtD
Sunitinib—CYP3A4—renal system—uterine cancer	3.09e-05	0.000247	CbGeAlD
Sunitinib—Paraesthesia—Doxorubicin—uterine cancer	3.07e-05	0.000266	CcSEcCtD
Sunitinib—Dyspnoea—Doxorubicin—uterine cancer	3.05e-05	0.000264	CcSEcCtD
Sunitinib—Gastrointestinal pain—Epirubicin—uterine cancer	3.02e-05	0.000262	CcSEcCtD
Sunitinib—Dyspepsia—Doxorubicin—uterine cancer	3.01e-05	0.00026	CcSEcCtD
Sunitinib—ABCB1—myometrium—uterine cancer	3.01e-05	0.00024	CbGeAlD
Sunitinib—CYP3A5—female gonad—uterine cancer	3e-05	0.00024	CbGeAlD
Sunitinib—CYP3A5—vagina—uterine cancer	2.98e-05	0.000238	CbGeAlD
Sunitinib—Decreased appetite—Doxorubicin—uterine cancer	2.97e-05	0.000257	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Doxorubicin—uterine cancer	2.95e-05	0.000255	CcSEcCtD
Sunitinib—Fatigue—Doxorubicin—uterine cancer	2.95e-05	0.000255	CcSEcCtD
Sunitinib—ABCC4—lymph node—uterine cancer	2.94e-05	0.000235	CbGeAlD
Sunitinib—Pain—Doxorubicin—uterine cancer	2.93e-05	0.000253	CcSEcCtD
Sunitinib—Constipation—Doxorubicin—uterine cancer	2.93e-05	0.000253	CcSEcCtD
Sunitinib—Body temperature increased—Epirubicin—uterine cancer	2.92e-05	0.000253	CcSEcCtD
Sunitinib—Abdominal pain—Epirubicin—uterine cancer	2.92e-05	0.000253	CcSEcCtD
Sunitinib—ABCC2—lymph node—uterine cancer	2.85e-05	0.000228	CbGeAlD
Sunitinib—Gastrointestinal pain—Doxorubicin—uterine cancer	2.8e-05	0.000242	CcSEcCtD
Sunitinib—Hypersensitivity—Epirubicin—uterine cancer	2.72e-05	0.000236	CcSEcCtD
Sunitinib—Abdominal pain—Doxorubicin—uterine cancer	2.7e-05	0.000234	CcSEcCtD
Sunitinib—Body temperature increased—Doxorubicin—uterine cancer	2.7e-05	0.000234	CcSEcCtD
Sunitinib—Asthenia—Epirubicin—uterine cancer	2.65e-05	0.000229	CcSEcCtD
Sunitinib—Pruritus—Epirubicin—uterine cancer	2.62e-05	0.000226	CcSEcCtD
Sunitinib—Diarrhoea—Epirubicin—uterine cancer	2.53e-05	0.000219	CcSEcCtD
Sunitinib—Hypersensitivity—Doxorubicin—uterine cancer	2.52e-05	0.000218	CcSEcCtD
Sunitinib—CYP3A4—female reproductive system—uterine cancer	2.48e-05	0.000198	CbGeAlD
Sunitinib—Asthenia—Doxorubicin—uterine cancer	2.45e-05	0.000212	CcSEcCtD
Sunitinib—Dizziness—Epirubicin—uterine cancer	2.44e-05	0.000211	CcSEcCtD
Sunitinib—Pruritus—Doxorubicin—uterine cancer	2.42e-05	0.000209	CcSEcCtD
Sunitinib—ABCB1—epithelium—uterine cancer	2.36e-05	0.000189	CbGeAlD
Sunitinib—Vomiting—Epirubicin—uterine cancer	2.35e-05	0.000203	CcSEcCtD
Sunitinib—Diarrhoea—Doxorubicin—uterine cancer	2.34e-05	0.000202	CcSEcCtD
Sunitinib—ABCB1—uterine cervix—uterine cancer	2.34e-05	0.000187	CbGeAlD
Sunitinib—KCNH2—lymph node—uterine cancer	2.34e-05	0.000187	CbGeAlD
Sunitinib—Rash—Epirubicin—uterine cancer	2.33e-05	0.000202	CcSEcCtD
Sunitinib—Dermatitis—Epirubicin—uterine cancer	2.33e-05	0.000201	CcSEcCtD
Sunitinib—Headache—Epirubicin—uterine cancer	2.32e-05	0.0002	CcSEcCtD
Sunitinib—Dizziness—Doxorubicin—uterine cancer	2.26e-05	0.000196	CcSEcCtD
Sunitinib—ABCB1—decidua—uterine cancer	2.23e-05	0.000178	CbGeAlD
Sunitinib—Nausea—Epirubicin—uterine cancer	2.2e-05	0.00019	CcSEcCtD
Sunitinib—ABCB1—renal system—uterine cancer	2.19e-05	0.000175	CbGeAlD
Sunitinib—Vomiting—Doxorubicin—uterine cancer	2.17e-05	0.000188	CcSEcCtD
Sunitinib—Rash—Doxorubicin—uterine cancer	2.16e-05	0.000187	CcSEcCtD
Sunitinib—Dermatitis—Doxorubicin—uterine cancer	2.15e-05	0.000186	CcSEcCtD
Sunitinib—Headache—Doxorubicin—uterine cancer	2.14e-05	0.000185	CcSEcCtD
Sunitinib—ABCB1—endometrium—uterine cancer	2.12e-05	0.000169	CbGeAlD
Sunitinib—ABCG2—lymph node—uterine cancer	2.08e-05	0.000166	CbGeAlD
Sunitinib—ABCB1—mammalian vulva—uterine cancer	2.05e-05	0.000164	CbGeAlD
Sunitinib—Nausea—Doxorubicin—uterine cancer	2.03e-05	0.000176	CcSEcCtD
Sunitinib—ABCB1—uterus—uterine cancer	1.95e-05	0.000156	CbGeAlD
Sunitinib—ABCB1—female reproductive system—uterine cancer	1.75e-05	0.00014	CbGeAlD
Sunitinib—ABCB1—female gonad—uterine cancer	1.59e-05	0.000127	CbGeAlD
Sunitinib—ABCB1—vagina—uterine cancer	1.58e-05	0.000127	CbGeAlD
Sunitinib—ABCB1—lymph node—uterine cancer	1.02e-05	8.19e-05	CbGeAlD
Sunitinib—KDR—Signaling Pathways—KRAS—uterine cancer	8.6e-07	5.69e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EP300—uterine cancer	8.54e-07	5.65e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—PIK3CA—uterine cancer	8.48e-07	5.61e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—KRAS—uterine cancer	8.47e-07	5.6e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CTNNB1—uterine cancer	8.45e-07	5.59e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TP53—uterine cancer	8.45e-07	5.59e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CXCL8—uterine cancer	8.44e-07	5.58e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CTNNB1—uterine cancer	8.43e-07	5.58e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EP300—uterine cancer	8.43e-07	5.57e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—KRAS—uterine cancer	8.43e-07	5.57e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—PIK3CA—uterine cancer	8.41e-07	5.56e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—HRAS—uterine cancer	8.38e-07	5.54e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—AKT1—uterine cancer	8.38e-07	5.54e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—ERBB2—uterine cancer	8.37e-07	5.53e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—PIK3CA—uterine cancer	8.36e-07	5.53e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—HRAS—uterine cancer	8.34e-07	5.52e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—VEGFA—uterine cancer	8.33e-07	5.51e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—ERBB2—uterine cancer	8.32e-07	5.5e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—KRAS—uterine cancer	8.32e-07	5.5e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—HRAS—uterine cancer	8.32e-07	5.5e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—PIK3CA—uterine cancer	8.3e-07	5.49e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—HRAS—uterine cancer	8.3e-07	5.49e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EP300—uterine cancer	8.28e-07	5.48e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EP300—uterine cancer	8.28e-07	5.48e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—PIK3CA—uterine cancer	8.28e-07	5.47e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—PIK3CA—uterine cancer	8.28e-07	5.47e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CDKN1B—uterine cancer	8.24e-07	5.45e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—PTEN—uterine cancer	8.24e-07	5.45e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—HRAS—uterine cancer	8.24e-07	5.45e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CXCL8—uterine cancer	8.23e-07	5.44e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—NRAS—uterine cancer	8.22e-07	5.44e-06	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—AKT1—uterine cancer	8.22e-07	5.44e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—PTEN—uterine cancer	8.22e-07	5.43e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—RRM2—uterine cancer	8.15e-07	5.39e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TP53—uterine cancer	8.14e-07	5.38e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—KRAS—uterine cancer	8.12e-07	5.37e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—PIK3CA—uterine cancer	8.1e-07	5.36e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—PIK3CA—uterine cancer	8.1e-07	5.36e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—PIK3CA—uterine cancer	8.1e-07	5.36e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—HRAS—uterine cancer	8.09e-07	5.35e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TP53—uterine cancer	8.09e-07	5.35e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—VEGFA—uterine cancer	8.08e-07	5.35e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—HRAS—uterine cancer	8.08e-07	5.34e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—PIK3CA—uterine cancer	8.08e-07	5.34e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—KRAS—uterine cancer	8.06e-07	5.33e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CDKN1B—uterine cancer	8.04e-07	5.32e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—NRAS—uterine cancer	7.98e-07	5.28e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—VEGFA—uterine cancer	7.98e-07	5.28e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—AKT1—uterine cancer	7.98e-07	5.28e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—ERBB2—uterine cancer	7.95e-07	5.26e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CXCL8—uterine cancer	7.94e-07	5.25e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—DCN—uterine cancer	7.91e-07	5.23e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—PIK3CA—uterine cancer	7.9e-07	5.22e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CXCL8—uterine cancer	7.89e-07	5.22e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—NRAS—uterine cancer	7.89e-07	5.22e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—AKT1—uterine cancer	7.88e-07	5.21e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—AKT1—uterine cancer	7.86e-07	5.2e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EP300—uterine cancer	7.86e-07	5.2e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—HRAS—uterine cancer	7.84e-07	5.19e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—VEGFA—uterine cancer	7.84e-07	5.19e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—VEGFA—uterine cancer	7.84e-07	5.19e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TP53—uterine cancer	7.84e-07	5.19e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TP53—uterine cancer	7.84e-07	5.19e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EP300—uterine cancer	7.84e-07	5.18e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—KRAS—uterine cancer	7.82e-07	5.17e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—AKT1—uterine cancer	7.79e-07	5.15e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—PIK3CA—uterine cancer	7.79e-07	5.15e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CTNNB1—uterine cancer	7.78e-07	5.15e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—HRAS—uterine cancer	7.78e-07	5.15e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—KRAS—uterine cancer	7.78e-07	5.15e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CDKN1B—uterine cancer	7.75e-07	5.13e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—NRAS—uterine cancer	7.74e-07	5.12e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—NRAS—uterine cancer	7.74e-07	5.12e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—PIK3CA—uterine cancer	7.74e-07	5.12e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—AKT1—uterine cancer	7.74e-07	5.12e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—AKT1—uterine cancer	7.74e-07	5.12e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—HRAS—uterine cancer	7.73e-07	5.11e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CDKN1B—uterine cancer	7.71e-07	5.1e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—HRAS—uterine cancer	7.68e-07	5.08e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—HRAS—uterine cancer	7.66e-07	5.07e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—HRAS—uterine cancer	7.66e-07	5.06e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—PIK3CA—uterine cancer	7.64e-07	5.05e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—uterine cancer	7.64e-07	5.05e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CTNNB1—uterine cancer	7.6e-07	5.02e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PTEN—uterine cancer	7.59e-07	5.02e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CXCL8—uterine cancer	7.54e-07	4.99e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—HRAS—uterine cancer	7.5e-07	4.96e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—HRAS—uterine cancer	7.5e-07	4.96e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—HRAS—uterine cancer	7.49e-07	4.96e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—HRAS—uterine cancer	7.47e-07	4.94e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—KRAS—uterine cancer	7.46e-07	4.94e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—PIK3CA—uterine cancer	7.46e-07	4.93e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP11A1—uterine cancer	7.45e-07	4.93e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—VEGFA—uterine cancer	7.44e-07	4.92e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—KRAS—uterine cancer	7.44e-07	4.92e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—VEGFA—uterine cancer	7.42e-07	4.91e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PTEN—uterine cancer	7.4e-07	4.9e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—PIK3CA—uterine cancer	7.4e-07	4.89e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—AKT1—uterine cancer	7.4e-07	4.89e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CDKN1B—uterine cancer	7.37e-07	4.87e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—AKT1—uterine cancer	7.37e-07	4.87e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—NRAS—uterine cancer	7.35e-07	4.86e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—AKT1—uterine cancer	7.34e-07	4.86e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—NRAS—uterine cancer	7.33e-07	4.85e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—AKT1—uterine cancer	7.32e-07	4.84e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CTNNB1—uterine cancer	7.32e-07	4.84e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—HRAS—uterine cancer	7.31e-07	4.83e-06	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—AKT1—uterine cancer	7.29e-07	4.82e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CTNNB1—uterine cancer	7.28e-07	4.82e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—AKT1—uterine cancer	7.27e-07	4.81e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EP300—uterine cancer	7.23e-07	4.78e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—HRAS—uterine cancer	7.2e-07	4.76e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—PIK3CA—uterine cancer	7.19e-07	4.75e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HRAS—uterine cancer	7.16e-07	4.74e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PIK3CA—uterine cancer	7.15e-07	4.73e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—AKT1—uterine cancer	7.14e-07	4.72e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PTEN—uterine cancer	7.14e-07	4.72e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—AKT1—uterine cancer	7.13e-07	4.72e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PTEN—uterine cancer	7.1e-07	4.69e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KRAS—uterine cancer	7.08e-07	4.68e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—HRAS—uterine cancer	7.07e-07	4.68e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EP300—uterine cancer	7.06e-07	4.67e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKR1C3—uterine cancer	7.04e-07	4.66e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CTNNB1—uterine cancer	6.96e-07	4.6e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—AKT1—uterine cancer	6.92e-07	4.58e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—HRAS—uterine cancer	6.9e-07	4.56e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTEN—uterine cancer	6.88e-07	4.55e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KRAS—uterine cancer	6.87e-07	4.55e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—AKT1—uterine cancer	6.87e-07	4.54e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—PIK3CA—uterine cancer	6.86e-07	4.54e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—VEGFA—uterine cancer	6.85e-07	4.53e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HRAS—uterine cancer	6.85e-07	4.53e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—PIK3CA—uterine cancer	6.83e-07	4.52e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—AKT1—uterine cancer	6.83e-07	4.52e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTEN—uterine cancer	6.82e-07	4.51e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EP300—uterine cancer	6.8e-07	4.5e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KRAS—uterine cancer	6.79e-07	4.49e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PTEN—uterine cancer	6.78e-07	4.49e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—AKT1—uterine cancer	6.78e-07	4.48e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EP300—uterine cancer	6.77e-07	4.48e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NRAS—uterine cancer	6.77e-07	4.48e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—AKT1—uterine cancer	6.76e-07	4.47e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—AKT1—uterine cancer	6.76e-07	4.47e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—MTHFR—uterine cancer	6.69e-07	4.42e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—VEGFA—uterine cancer	6.69e-07	4.42e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KRAS—uterine cancer	6.67e-07	4.41e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—KRAS—uterine cancer	6.67e-07	4.41e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—HRAS—uterine cancer	6.65e-07	4.4e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—uterine cancer	6.63e-07	4.39e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—AKT1—uterine cancer	6.62e-07	4.38e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—AKT1—uterine cancer	6.62e-07	4.38e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—AKT1—uterine cancer	6.62e-07	4.38e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—HRAS—uterine cancer	6.62e-07	4.38e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NRAS—uterine cancer	6.6e-07	4.37e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—AKT1—uterine cancer	6.6e-07	4.36e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—EP300—uterine cancer	6.56e-07	4.34e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—EP300—uterine cancer	6.51e-07	4.3e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—PIK3CA—uterine cancer	6.5e-07	4.3e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EP300—uterine cancer	6.47e-07	4.28e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—AKT1—uterine cancer	6.45e-07	4.27e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—VEGFA—uterine cancer	6.44e-07	4.26e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—VEGFA—uterine cancer	6.41e-07	4.24e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NRAS—uterine cancer	6.37e-07	4.21e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—AKT1—uterine cancer	6.36e-07	4.21e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HRAS—uterine cancer	6.34e-07	4.2e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NRAS—uterine cancer	6.33e-07	4.19e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—AKT1—uterine cancer	6.33e-07	4.18e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KRAS—uterine cancer	6.33e-07	4.18e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—HRAS—uterine cancer	6.32e-07	4.18e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—PIK3CA—uterine cancer	6.31e-07	4.18e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KRAS—uterine cancer	6.31e-07	4.17e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—uterine cancer	6.29e-07	4.16e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—AKT1—uterine cancer	6.24e-07	4.13e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—PIK3CA—uterine cancer	6.24e-07	4.12e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—VEGFA—uterine cancer	6.13e-07	4.05e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—PIK3CA—uterine cancer	6.12e-07	4.05e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—PIK3CA—uterine cancer	6.12e-07	4.05e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—uterine cancer	6.11e-07	4.04e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—AKT1—uterine cancer	6.09e-07	4.03e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NRAS—uterine cancer	6.05e-07	4e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—AKT1—uterine cancer	6.05e-07	4e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—uterine cancer	6.03e-07	3.99e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HRAS—uterine cancer	6.02e-07	3.98e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—uterine cancer	5.92e-07	3.92e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—uterine cancer	5.92e-07	3.92e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—AKT1—uterine cancer	5.87e-07	3.88e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HRAS—uterine cancer	5.84e-07	3.86e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—AKT1—uterine cancer	5.84e-07	3.86e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KRAS—uterine cancer	5.82e-07	3.85e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—PIK3CA—uterine cancer	5.81e-07	3.84e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—PIK3CA—uterine cancer	5.8e-07	3.83e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HRAS—uterine cancer	5.77e-07	3.82e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KRAS—uterine cancer	5.68e-07	3.76e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HRAS—uterine cancer	5.67e-07	3.75e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HRAS—uterine cancer	5.67e-07	3.75e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—uterine cancer	5.62e-07	3.72e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—uterine cancer	5.61e-07	3.71e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—AKT1—uterine cancer	5.6e-07	3.7e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—AKT1—uterine cancer	5.58e-07	3.69e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP19A1—uterine cancer	5.48e-07	3.63e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—STK11—uterine cancer	5.48e-07	3.63e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KRAS—uterine cancer	5.48e-07	3.62e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KRAS—uterine cancer	5.45e-07	3.6e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HRAS—uterine cancer	5.38e-07	3.56e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HRAS—uterine cancer	5.36e-07	3.55e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PIK3CA—uterine cancer	5.35e-07	3.54e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—AKT1—uterine cancer	5.31e-07	3.51e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PIK3CA—uterine cancer	5.22e-07	3.45e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KRAS—uterine cancer	5.21e-07	3.44e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—uterine cancer	5.18e-07	3.42e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—AKT1—uterine cancer	5.16e-07	3.41e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—AKT1—uterine cancer	5.09e-07	3.37e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—uterine cancer	5.05e-07	3.34e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PIK3CA—uterine cancer	5.03e-07	3.33e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PIK3CA—uterine cancer	5.01e-07	3.31e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—AKT1—uterine cancer	5e-07	3.31e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—AKT1—uterine cancer	5e-07	3.31e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRAS—uterine cancer	4.95e-07	3.27e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTEN—uterine cancer	4.93e-07	3.26e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—uterine cancer	4.87e-07	3.22e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PIK3CA—uterine cancer	4.86e-07	3.21e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—uterine cancer	4.84e-07	3.2e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRAS—uterine cancer	4.83e-07	3.2e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PIK3CA—uterine cancer	4.81e-07	3.18e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PIK3CA—uterine cancer	4.78e-07	3.16e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—AKT1—uterine cancer	4.75e-07	3.14e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—AKT1—uterine cancer	4.74e-07	3.13e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—EP300—uterine cancer	4.7e-07	3.11e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRAS—uterine cancer	4.66e-07	3.08e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRAS—uterine cancer	4.63e-07	3.06e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—uterine cancer	4.63e-07	3.06e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRAS—uterine cancer	4.43e-07	2.93e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—AKT1—uterine cancer	4.37e-07	2.89e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—AKT1—uterine cancer	4.27e-07	2.82e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—MTHFR—uterine cancer	4.12e-07	2.73e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—AKT1—uterine cancer	4.11e-07	2.72e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—AKT1—uterine cancer	4.09e-07	2.71e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—AKT1—uterine cancer	3.97e-07	2.62e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—AKT1—uterine cancer	3.93e-07	2.6e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—AKT1—uterine cancer	3.91e-07	2.59e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTEN—uterine cancer	3.72e-07	2.46e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—EP300—uterine cancer	3.55e-07	2.35e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CA—uterine cancer	3.48e-07	2.3e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—AKT1—uterine cancer	2.84e-07	1.88e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CA—uterine cancer	2.63e-07	1.74e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTEN—uterine cancer	2.29e-07	1.52e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—EP300—uterine cancer	2.19e-07	1.45e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—AKT1—uterine cancer	2.14e-07	1.42e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.62e-07	1.07e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKT1—uterine cancer	1.32e-07	8.74e-07	CbGpPWpGaD
